Cargando…

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study

Objective: Adalimumab (ADA) is an effective treatment for inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn’s disease (CD). The equal effect between the original ADA and biosimilars from Europe and the United States has been shown. However, the biosimilar of ADA is different i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fang, Li, Xiaofei, Shi, Yanting, Zhou, He, Yang, Gang, Li, Ruixia, Wu, Tong, Liang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613675/ https://www.ncbi.nlm.nih.gov/pubmed/37908975 http://dx.doi.org/10.3389/fphar.2023.1259183

Ejemplares similares

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points
por: Su, Jinmei, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
por: Su, Jinmei, et al.
Publicado: (2020)

Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study
por: Su, Jinmei, et al.
Publicado: (2021)

A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects
por: Cao, Guoying, et al.
Publicado: (2020)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
por: Vernero, Marta, et al.
Publicado: (2023)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
por: Mocci, Giammarco, et al.
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
por: Popescu, Claudiu Costinel, et al.
Publicado: (2022)

T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
por: Cingolani, A., et al.
Publicado: (2022)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

A175 REAL-WORLD EXPERIENCE ON SWITCHING FROM ADALIMUMAB TO BIOSIMILARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – AN OBSERVATIONAL STUDY FROM THREE TERTIARY CARE CENTRES
por: Bedi, H, et al.
Publicado: (2023)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
por: Zhang, Hong, et al.
Publicado: (2021)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

A208 REAL WORLD EVIDENCE ANALYSIS WITH ADALIMUMAB BIOSIMILAR, MSB 11022, REPORTED WITH PATIENT CARE PROGRAM
por: Cheung, S, et al.
Publicado: (2023)

Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
por: Kirsten, Natalia, et al.
Publicado: (2022)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Adalimumab in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2022)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
por: Carballo, Nuria, et al.
Publicado: (2022)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Li, Biao, et al.
Publicado: (2021)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
por: Midha, Vandana, et al.
Publicado: (2018)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_reaj6ckjs2mudk492n6st403b8